AstraZeneca has announced the launch of Evinova, a new health-tech business aimed at sharing its expertise in clinical trial design and study delivery. This separate business will focus on providing solutions to trial sponsors, clinical research organizations, care teams, and patients at a larger scale. The pharmaceutical giant expects this initiative to reduce the time and cost of developing new medicines, bring care closer to patients’ homes, and decrease the burden on health systems.

To bring Evinova’s solutions to a wider audience, AstraZeneca has formed major collaborations with Parexel and Fortrea. These partnerships will allow Evinova’s digital health solutions to be made available to a broad customer base, supporting the company’s mission to fundamentally improve patient care, drive healthcare transformation, and reduce carbon emissions.

In an interview with CNBC’s Jim Cramer, Pascal Soriot, CEO of AstraZeneca expressed his confidence in Evinova’s ability to combine scientific expertise with AI-enabled digital technologies at scale, offering a real opportunity for positive change in the healthcare industry.

For more information about Evinova or any other AstraZeneca initiatives please contact Michael Susin at michael.susin@wsj.com